



Fact sheet references

- Baker MF, McNicholas AM, Garrett NM, Jones NF, Stewart JM, Koberstein V, et al. Household crowding a major risk factor for epidemic meningococcal disease in Auckland children. *Pediatr Infect Dis J*. 2000;19(10):983-90.
- Baxter R, Baine Y, Kolhe D, Baccarini CI, Miller JM, Van der Wielen M. Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in adolescents and young adults: An open, randomized trial. *Pediatr Infect Dis J*. 2015;34(11):1236-43.
- Campagne GMM, Garba AM, Fabre PMM, Schuchat AM, Ryall RP, Boulanger DM, et al. Safety and immunogenicity of three doses of a *Neisseria meningitidis* A + C diphtheria conjugate vaccine in infants from Niger. *Pediatr Infect Dis J*. 2000;19(2):144.
- Flacco ME, Manzoli L, Rosso A, Marzuillo C, Bergamini M, Stefanati A, et al. Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: A systematic review and meta-analysis. *Lancet Infect Dis*. 2018;18(4):461-72.
- Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: A randomized controlled trial. *JAMA*. 2012;307(6):573-82.
- Harrison L, Granoff D, Pollard, AJ. Meningococcal capsular group A, C, W, and Y conjugate vaccines. In: Plotkin S, Orenstein W, Offit P, Edwards K, editors. *Plotkin's Vaccines*. 7th ed. Philadelphia: Elsevier; 2018. p. 619-43.
- Hong E, Terrade A, Taha M-K. Immunogenicity and safety among laboratory workers vaccinated with Bexsero vaccine. *Hum Vaccin Immunother*. 2017;13(3):645-8.
- Institute of Environmental Science and Research Ltd. Meningococcal disease quarterly report Jan - Dec 2019. Porirua: Institute of Environmental Science and Research Ltd (ESR); 2020.
- Iro MA, Snape MD, Voysey M, Jawad S, Finn A, Heath PT, et al. Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age - A phase 3 extension to a randomised controlled trial. *Vaccine*. 2017;35(2):395-402.
- Kanabar DJ. A clinical and safety review of paracetamol and ibuprofen in children. *Inflammopharmacology*. 2017;25(1):1-9.
- Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. *Arch Pediatr Adolesc Med*. 2005;159(10):907-13.
- Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. *Clin Vaccine Immunol*. 2011;18(3):483-6.
- Lopez L, Sherwood J. The epidemiology of meningococcal disease in New Zealand 2013. Wellington: Institute of Environmental Science and Research Ltd (ESR); 2014. Report No.: FW14023.
- Martinon-Torres F, Safadi MAP, Martinez AC, Marquez PI, Torres JCT, Weckx LY, et al. Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial. *Vaccine*. 2017;35(28):3548-57.
- Martinon-Torres F, Carmona Martinez A, Simko R, Marquez PI, Arimany J-L, Gimenez-Sanchez F, et al. Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial. *J Infect*. 2018;76(3):258-69.
- McCall BJ, Neill AS, Young MM. Risk factors for invasive meningococcal disease in southern Queensland, 2000-2001. *Intern Med J*. 2004;34(8):464-8.
- Medsafe. The relevant vaccine data sheet [Internet]. Wellington: New Zealand Medicines and Medical Devices Safety Authority. Available from: <http://www.medsafe.govt.nz/>.
- Ministry of Health. Immunisation handbook 2017 2nd Edition [Internet]. Wellington: Ministry of Health; 2017 [cited 2018 August 24]. Available from: <https://www.health.govt.nz/publication/immunisation-handbook-2017>.
- Musher DM. How contagious are common respiratory tract infections? *N Engl J Med*. 2003;348(13):1256-66.
- Fact sheet: Meningococcal vaccines for Australians [Internet]. Sydney: National Centre for Immunisation Research and Surveillance (NCIRS) [updated 2019 April; cited 2019 May 13]. Available from: <http://www.ncirs.org.au/ncirs-fact-sheets-faqs/meningococcal-vaccines-australians>.
- Nokleby H. Vaccination and anaphylaxis. *Curr Allergy Asthma Rep*. 2006;6(1):9-13.
- Orr HJ, Gray SJ, Macdonald M, Stuart JM. Saliva and meningococcal transmission. *Emerg Infect Dis*. 2003;9(10):1314-5.
- The UK immunisation schedule [Internet]. Oxford: Oxford Vaccine Group. [updated 2018 May 9; cited 2019 May 13]. Available from: <http://vk.ovg.ox.ac.uk/uk-schedule>.
- Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, et al. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: A national observational cohort study. *Lancet*. 2016;388(10061):2775-82.
- Peterson ME, Mile R, Li Y, Nair H, Kyaw MH. Meningococcal carriage in high-risk settings: A systematic review. *Int J Infect Dis*. 2018;73:109-17.
- Pichichero M, Casey J, Blatter M, Rothstein E, Ryall R, Bybel M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children. *Pediatr Infect Dis J*. 2005;24(1):57-62.
- Childhood immunisation programme [Internet]. Adelaide: SA Health; 2012 [updated 2019 May 6; cited 2019 May 13]. Available from: <https://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/health+topics/health+conditions+prevention+and+treatment/immunisation/immunisation+programs/childhood+immunisation+program>.
- Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and *Neisseria meningitidis*. *Lancet*. 2007;369(9580):2196-210.
- Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: Results of two randomised trials. *Lancet*. 2013;381(9869):825-35.
- Virji M. Pathogenic *Neisseriae*: surface modulation, pathogenesis and infection control. *Nat Rev Microbiol*. 2009;7(4):274-86.
- Watson PS, Turner DPJ. Clinical experience with the meningococcal B vaccine, Bexsero: Prospects for reducing the burden of meningococcal serogroup B disease. *Vaccine*. 2016;34(7):875-80.
- World Health Organization. The immunological basis for immunization series: Module 15: Meningococcal disease. Geneva: World Health Organization, 2010.
- Wysocki J, Center KJ, Brzostek J, Majda-Stanislawski E, Szymanski H, Szenborn L, et al. A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations. *Vaccine*. 2017;35(15):1926-35.